Clinical Trials Arena March 4, 2024
The study looked at medical records of more than three million diabetic patients and almost one million non-diabetic patients.
A study claims that there is a link between weight-loss drugs and a reduced risk of depression and anxiety.
The study, which reviewed the medical records of over three million diabetic patients and almost one million non-diabetic patients, found that patients prescribed glucagon such as peptide-1 receptor agonists (GLP1-RA) medications such as Wegovy and Mounjaro were less likely to be diagnosed with depression and anxiety.
GLP1-RA drugs have taken the type 2 diabetes and obesity market by storm with market leaders Novo Nordisk and Eli Lilly becoming the two biggest pharmaceutical companies in the world. As a result, the candidates are...
Today's Sponsors
Today's Sponsor